ArticleNature reviews. Disease primers2024
Guillain-Barré syndrome.
Article in Nature reviews. Disease primers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Neurofilament light chain improves clinical prognostic models for Guillain-Barré syndrome.Journal of neurology, neurosurgery, and psychiatry · 2025Trial
- Risk factors for hypotension and technical complications during single-session double-filtration plasmapheresis: a 15-year retrospective study of 1,022 procedures.Renal failure · 2026Article
- Multiple organ failure following severe heat stroke complicated by AMSAN-type Guillain-Barré syndrome: a case report and literature review.BMC neurology · 2026Review
- Frequency and Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Accompanied by Fever: A Single-Center Retrospective Study.CNS neuroscience & therapeutics · 2026Article
- Article
- Guillain-Barré Syndrome Revealing Coexisting Cervical Spondylotic Myelopathy: A Diagnostic Pitfall.Cureus · 2026Article
- Article
- Acute Management of Guillain-Barré Syndrome: A Narrative Review.Archives of internal medicine research · 2026Article
- Article
- Dynamic Changes and Future Trend Forecasts in the Global Burden of Guillain-Barré Syndrome: Analysis of 204 Countries and Regions From 1990 to 2021, Including the Impact of the COVID-19 Pandemic.Immunity, inflammation and disease · 2026Observational
- Miller Fisher Syndrome With Guillain-Barré Syndrome Overlap in a 20-Month-Old Girl: A Case Report.Cureus · 2026Article
- Acute Small Fiber Neuropathy With Severe Autonomic Dysfunction at the Interface of Guillain-Barré Syndrome.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Lessons from a Severe Case of Fulminant Guillain-Barré Syndrome: A Case Report.Reports (MDPI) · 2026Article
- ActIIR inhibition improves motor outcome and preserves muscle fibers after experimental autoimmune neuritis.Acta neuropathologica communications · 2026Article
- A long-term observational study on autoimmune pulmonary alveolar proteinosis revealed a sustained and generalized decrease in serum autoantibody levels.Orphanet journal of rare diseases · 2026Observational
- Clinical profile and predictors of guillain-barre syndrome associated pneumonia: a retrospective cohort study.BMC neurology · 2026Article
- Data-driven spatial-temporal framework for exploring the heterogeneity and temporality of sepsis.Chinese medical journal · 2026Review
- POEMS syndrome with multiple ganglioside/paraneoplastic antibodies misdiagnosed as CIDP: a case report.Frontiers in oncology · 2026Article
- Guillain-Barré Syndrome: Progress in Diagnosis, Biomarkers, Neuroimaging and Management.ImmunoTargets and therapy · 2026Review
- Clinical outcomes and safety of efgartigimod in Guillain-Barré syndrome: a retrospective observation study.Frontiers in immunology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guillain-Barré syndrome (GBS) is a rare immune-mediated polyradiculoneuropathy. Patients typically develop rapidly progressive weakness and sensory deficits that can result in complete paralysis requiring mechanical ventilation. GBS is usually a monophasic disease in which an aberrant immune response to an infection or other trigger damages the peripheral nerves. For example, in patients with preceding Campylobacter jejuni infection, molecular mimicry causes a cross-reactive antibody response to nerve gangliosides. Diagnosis is based on clinical features, supported by cerebrospinal fluid analysis and nerve conduction studies. Effective treatments include plasma exchange and intravenous immunoglobulins. However, ~20% of patients who received treatment are unable to walk after 6 months and ~5% die as a consequence of GBS. Important knowledge gaps in GBS include its pathogenesis, especially after viral infections. In addition, there is a lack of specific biomarkers to improve the diagnosis, monitor the disease activity, and predict the clinical course and outcome of GBS. Major challenges for the future include finding more effective and personalized treatments, which are affordable in low-income and middle-income countries, and preparation for outbreaks of infections as potential triggers for GBS.
Indexed as
Identifiers
39702645What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.